Business
Proposed Board Change
Proposed Board Change.
About this update from Valirx Plc
[{"type":"text","content":"\n \n \n RNS Number : 0664O\n ValiRx PLC\n 27 May 2020\n \n \n \n \n \n \n \n \n \n \n VALIRX PLC\n \n \n (\"ValiRx\", the \"Company\" or the \"Group\")\n \n \n Proposed Board Change\n \n \n \n \n \n \n London, UK\n \n ., 27 May 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces that subject to the completion of the satisfactory background checks, it intends to appoint Dr Kevin Cox as a director of the Company in the position as Non-executive Chairman.\n \n \n \n \n \n Kevin has over 25 years' experience in the life science industry, covering a wide range of sectors such as biomanufacturing, anti-infectives development, biomedical imaging, pathology, and clinical pharmacology. Serving as CEO of high growth biotechnology businesses, he has extensive experience in strategy, corporate development, M&A, financing and joint ventures. \n \n \n \n \n \n Kevin has a background in improving translational science, Kevin has developed strong links to government, funding bodies and academia, and has contributed to a number of public sector advisory committees. Kevin currently has non-executive roles with Biorelate Limited, Syndermix SA and the British Neuroscience Association, and is Chief Executive Officer at Biotaspheric Limited.\n \n \n \n \n \n A further announcement will made in due course.\n \n \n \n \n \n This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n \n \n \n \n \n \n \n For more information, please contact:\n \n \n \n \n \n \n \n \n ValiRx plc\n \n \n Kevin Alexander, Non-executive Director\n \n \n \n \n \n \n \n Tel: +44 (0) 20 7073 2628\n \n \n \n www.valirx.com\n \n \n \n \n \n \n \n \n Cairn Financial Advisers LLP (Nominated Adviser)\n \n \n \n \n Liam Murray / Jo Turner / Ludovico Lazzaretti\n \n \n \n \n \n \n \n Tel: +44 (0) 20 7213 0880\n \n \n \n \n \n \n Peterhouse Capital Limited (Sole Broker)\n \n \n Duncan Vasey / Lucy Williams / Eran Zucker\n \n \n \n \n \n \n \n Tel: +44 (0) 20 7469 0930\n \n \n \n \n \n \n \n \n Notes for Editors\n \n \n \n \n \n About ValiRx \n \n \n ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant c...